[A randomized controlled and multicenter clinical study of ferrous L-threonate in treatment of iron deficiency anemia].
OBJECTIVE
To study the clinical efficacy and side effects of ferrous L-threonate for treatment of iron deficiency anemia (IDA).


METHODS
It is a multicentral, randomized, double blind, double placebo and paralled comparative study with positive control. One hundred and forty IDA patients diagnosed according to the standard criteria in three hospitals were randomly divided into a test group (ferrous L-threonate plus placebo ferrous succinate) and a positive control group (ferrous succinate plus placebo ferrous L-threonate). Some iron parameters were examined 1, 4 and 8 weeks after medication. Hemoglobin, reticulocyte and other parameters for safety observation were collected every two weeks.


RESULTS
For the 2 groups, self comparison showed significant difference (P < 0.01). The total efficacy is 98.44% and 97.01% respectively with no difference. Hemoglobin rised rapidly and gradually and reached a peak in week 8, the change was statistically significant (P < 0.01). Changes of iron parameters also showed significant difference. Side-effects were similar in both groups (13.85% and 14.71%, P > 0.05).


CONCLUSIONS
The effect of ferrous L-threonate in IDA treatment is significant and rapid. Side-effects are few and minimal.
Li
Xiang-xin
XX
Department of Hemotology, Qilu Hospotal, Shandong University, Jinan 250012, China.
Chen
Xue-liang
XL
Zhang
Mao-hong
MH
Wang
Yan-hua
YH
Da
Wan-ming
WM
Li
Jian-yong
JY
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged
D005296:Ferrous Compounds; D005293:Ferritins; D007501:Iron